SBIR-STTR Award

  1. You are here:    Home
  2. Search Databases
  3. Search SBIR-STTR Awards
  4. SBIR-STTR Award

Clinical Trial Of A Novel Anti-Hiv Oligonucleotide
Award last edited on: 6/1/09

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$767,808
Award Phase
2
Solicitation Topic Code
-----
Principal Investigator
Thomas L Wallace

Company Information

Aronex Pharmaceuticals Inc (AKA: Argus Pharmacueticals~Triplex Pharmaceutical Corporation)

8707 Technology Forest Place
The Woodlands, TX 77381
   (281) 367-1666
   N/A
   www.aronex.com
Location: Multiple
Congr. District: 08
County: Montgomery

Phase I

Contract Number: 1R43AI038788-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1995
Phase I Amount
$100,000
The long term objective of this work is to determine the efficacy of a novel oligonucleotide drug (AR177) against HIV in humans. The primary aim of this grant is to perform a Phase Ib, multiple-dose clinical trial of AR177. Other aims are to perform a pharmacokinetic analysis of AR177 in the patient plasma from the Phase Ib clinical trial, and to determine the binding of AR177 to key blood constituents in vitro

Phase II

Contract Number: 2R44AI038788-02A1
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1997
(last award dollars: 1998)
Phase II Amount
$667,808
The long term objective of this work is to determine the efficacy of a novel oligonucleotide drug (AR177) against HIV in humans. The primary aim of this grant is to perform a Phase Ib, multiple-dose clinical trial of AR177. Other aims are to perform a pharmacokinetic analysis of AR177 in the patient plasma from the Phase Ib clinical trial, and to determine the binding of AR177 to key blood constituents in vitro.